Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns "Overweight" Rating from Cantor Fitzgerald theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective decreased by HC Wainwright from $35.00 to $33.00 in a research note issued to investors on Wednesday, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Crinetics Pharmaceuticals’ Q3 2023 earnings at ($0.83) EPS, Q4 2023 […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) has received an average rating of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have updated their coverage on the stock in the last […]
Monarch Partners Asset Management LLC cut its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) by 1.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 128,974 shares of the company’s stock after selling 1,886 shares during the quarter. Monarch Partners Asset Management LLC’s holdings in Crinetics Pharmaceuticals were worth $2,360,000 as of […]
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) have been assigned a consensus rating of “Buy” from the five brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued ratings on the stock […]